Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Deutsche Bank Keeps 'Buy' on 'MedImmune'

Deutsche Bank reiterates buy on MedImmune (MEDI).

An FDA panel recommended approval of the drug maker's flu vaccine. Analyst Dennis Harp says he expects FluMist to fuel earnings per share growth in 2003 through 2006. He projects approval in the first half of 2003, prior to the start of the 2003 and 2004 flu season in the third quarter.

Harp says controversy over efficacy in the 50-64 age group could be easily addressed. He notes his near-term earnings estimates don't incorporate approval of this age group. Harp sees $1.04 2003 earnings per share, ahead of the Street's 96 cents estimate. He forecasts 30% earnings per share growth over the next three years, largely driven by FluMist. He has a $49 target.

blog comments powered by Disqus